Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.
Findings of a study using real-world data from REGARDS showed that prevalence of polypharmacy, defined as ≥10 medications, is high in older patients hospitalized for HF.
This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.
AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.
AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.
AHA 2020 Although the primary endpoint was just missed in the AFFIRM-AHF trial, the individual endpoint of total HF hospitalization was reduced by IV ferric carboxymaltose compared to placebo in patients with acute HF and iron deficiency.
HF biomarkers and CV risk factors were strongly associated with incident HF without any sex-related differences among women and men.
ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.
ESC 2020 The EMPEROR-Reduced trial showed that empagliflozin reduced the risk of CV death or HF hospitalization by 25% in HFrEF patients with or without diabetes, compared to placebo.
Results from the EMPEROR-Reduced trial showed that the SGLT2 inhibitor empagliflozin significantly reduced the risk of CV death or hospitalization for heart failure in HFrEF patients with or without diabetes.
Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.
This cross-trial analysis estimated that comprehensive disease-modifying pharmacological therapy in HFrEF patients reduces the hazard of CV death or hospital admission, compared with conventional therapy.